• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Nick Gallo

Pharma & Human Health

Novonesis and Novo Nordisk will explore new solutions to improve metabolic health

September 8, 2025 Nick Gallo

Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people. Novonesis and Novo Nordisk have entered a research partnership […]

Finance

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg®

July 2, 2025 Nick Gallo

MaaT Pharma announces the signature of a license and commercial agreement with Clinigen, a global specialty pharmaceutical services group and a leading European player in hospital distribution and market access, to streamline the pathway for […]

Pharma & Human Health

A virally-encoded tRNA neutralizes the PARIS antiviral defense system

September 1, 2024 Nick Gallo

Scientists at Montana State University have been studying unique immune systems for decades, and a research team in the Department of Microbiology and Cell Biology took another step forward with work described in a paper published […]

Pharma & Human Health

Viruses use freeloading genes as weapons

July 26, 2024 Nick Gallo

Curious bits of DNA tucked inside genomes across all kingdoms of life historically have been disregarded since they don’t seem to have a role to play in the competition for survival. Or so researchers thought. […]

Editor's Choice

Eligo Publishes a Landmark Study in Nature That Unlocks Genome Editing of Bacteria in the Gut

July 10, 2024 Nick Gallo

Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, publishes a landmark study in Nature that unlocks Genome Editing of Bacteria in the Gut. […]

Pharma & Human Health

Mayo scientists developing at-home swab tests for endometrial, ovarian cancer

July 4, 2024 Nick Gallo

Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there are no standard screenings for early detection […]

Editor's Choice

A New Path Toward Microbiome-Informed Precision Nutrition

June 24, 2024 Nick Gallo

ISB microbiome researchers have shown that microbial community-scale metabolic modeling can predict personalized short-chain-fatty-acid production profiles in the human gut. Their findings were published in the journal Nature Microbiology. Short-chain fatty acids (SCFAs) are beneficial […]

Pharma & Human Health

Resiliency shaped by activity in the gut microbiome and brain

June 24, 2024 Nick Gallo

A new UCLA Health study has found that resilient people exhibit neural activity in the brain regions associated with improved cognition and regulating of emotions, and were more mindful and better at describing their feelings. […]

Pharma & Human Health

AxisBiotix Acne food supplement consumer study reports positive data

June 18, 2024 Nick Gallo

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that AxisBiotix Limited (“AxisBiotix”), a wholly owned subsidiary of the Company, has finalised the analysis of the data from its AxisBiotix Acne […]

Finance

Seres Therapeutics Enters Into Memorandum Of Understanding For Vowst™ Asset Sale To Nestlé Health Science

June 6, 2024 Nick Gallo

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide […]

Pharma & Human Health

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study for the Prevention of Recurrent C. diff Infection

May 22, 2024 Nick Gallo

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 […]

Posts navigation

1 2 3 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter